Alvotech Adalimumab Biosimilar Switching Study Hits Key Date
Icelandic Firm Chasing First High-Concentration Adalimumab Biosimilar
Alvotech underlined that it could “save US consumers and taxpayers billions annually,” after hitting a key landmark in its Phase III switching study for its high concentration 100mg/ml biosimilar Humira product.
